

10/516083

ST12 C'd PCT/PTO 30 NOV 2004

PATENT
0508-1117

#3

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Gilles Francois Roger GUICHARD et al. Conf.

Application No. **NEW NATIONAL PHASE** Group

Filed November 30, 2004 Examiner

NOVEL MULTIMERIC MOLECULES, THE PREPARATION METHOD THEREOF AND USE
OF SAME FOR THE PREPARATION OF MEDICAMENTS**INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)**Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 30, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of the duty of disclosure under 37 C.F.R. § 1.56, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☐ Copies of the U.S. patents or publications are not submitted since the USPTO has waived their submission for applications filed after June 30, 2003.
- ☒ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☐ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should have been forwarded from the International Search Authority pursuant to the trilateral agreement between the USPTO, EPO and JPO, or they are U.S. patents or U.S. published applications. If copies are needed, please contact the undersigned.

ST12 Rec'd PCT/PTO 30 NOV 2004

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)a. ☒ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached non U.S. patents, non U.S. patent application publications, foreign publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ **FOREIGN SEARCH REPORT OR ACTION**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☒ **OTHER**

The following additional information is provided for the Examiner's consideration.

French Search Report

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON

Benoit Castel
Benoit Castel, Reg. No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

BC/ia

Enclosures: ☒ Form PTO-1449(s)
☒ Documents
☒ Foreign Search Report
☒ Other: French Search Report

10/516083
NEW NATIONAL PHASE

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Attorney Docket No.:
0508-1117

Applicant:
Gilles Francois Roger GUICHARD et al.

Filing Date:
November 30, 2004

Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 02/00893	1/3/2002	WIPO				
	WO 01/49866	7/12/2001	WIPO				
	WO 01/42298	6/14/2001	WIPO				
	WO 99/52877	10/21/1999	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	G AVERSA ET AL.: "CD40 ligand-CD40 interaction in Ig isotype switching in mature and immature human B cells" SEMINARS IN IMMUNOLOGY., vol. 6, 1994, pages 295-301, XP002237774 W.B. SAUNDERS COMPANY, PA., US ISSN: 1044-5323 the whole document
	L E HASWELL ET AL.: "Analysis of the oligomeric requirements for signaling by CD40 using soluble multimeric forms of its ligands, CD154" EUROPEAN JOURNAL OF IMMUNOLOGY vol. 31, no. 10, octobre 2001 (2001-10), pages 3094-3100, XP002237771 WEINHEIM, DE ISSN: 0014-2980
	Y-M HSU ET AL.: "Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes" JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 272, no. 2, 1997, pages 911-915, XP002237772 AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US ISSN: 0021-9258
	ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 392, no. 2, 15 August 2001 (2001-08-15), pages 208-218, XP002237773 NEW YORK, US, US ISSN: 0003-9861

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* English language abstract provided for the Examiner's convenience